GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intelgenx Technologies Corp (OTCPK:IGXT) » Definitions » Return-on-Tangible-Equity

Intelgenx Technologies (Intelgenx Technologies) Return-on-Tangible-Equity : 0.00% (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Intelgenx Technologies Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Intelgenx Technologies's annualized net income for the quarter that ended in Dec. 2023 was $-5.52 Mil. Intelgenx Technologies's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $-11.58 Mil. Therefore, Intelgenx Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was N/A%.

The historical rank and industry rank for Intelgenx Technologies's Return-on-Tangible-Equity or its related term are showing as below:

During the past 13 years, Intelgenx Technologies's highest Return-on-Tangible-Equity was 25.59%. The lowest was -4,772.32%. And the median was -107.94%.

IGXT's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -48.28
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Intelgenx Technologies Return-on-Tangible-Equity Historical Data

The historical data trend for Intelgenx Technologies's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelgenx Technologies Return-on-Tangible-Equity Chart

Intelgenx Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -207.39 - -638.25 -4,772.32 -

Intelgenx Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Intelgenx Technologies's Return-on-Tangible-Equity

For the Biotechnology subindustry, Intelgenx Technologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intelgenx Technologies's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intelgenx Technologies's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Intelgenx Technologies's Return-on-Tangible-Equity falls into.



Intelgenx Technologies Return-on-Tangible-Equity Calculation

Intelgenx Technologies's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-9.927/( (-3.423+-12.247 )/ 2 )
=-9.927/-7.835
=N/A %

Intelgenx Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-5.52/( (-10.906+-12.247)/ 2 )
=-5.52/-11.5765
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Intelgenx Technologies  (OTCPK:IGXT) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Intelgenx Technologies Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Intelgenx Technologies's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Intelgenx Technologies (Intelgenx Technologies) Business Description

Traded in Other Exchanges
Address
6420 Abrams, Ville Saint Laurent, QC, CAN, H4S 1Y2
Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. Intelegenx focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer and manufacturing scale-up, and commercial manufacturing. Its geographical segments are Europe, Canada, and United States.
Executives
Atai Life Sciences Ag 10 percent owner KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Atai Life Sciences N.v. 10 percent owner 524 BROADWAY, NEW YORK NY 10013
Karen Kalayajian officer: VP, Finance&Admin - Subsidiary 4896 RUE EDOUARD-BRUNETTE, LAVAL A8 H7T 0J4
Dwight Gorham officer: CEO 15B BARKLEY ST, ARNPRIOR A6 K7S 3G8
David Kideckel officer: SVP, Corp. Dev&SA - Subsidiary 23 PEVERIL HILL SOUTH, TORONTO, ON A6 M6C 3A7
Horst G Zerbe 10 percent owner, officer: Chief Executive Officer 714 MAIN ROAD, HUDSON A8 JOP1H0
Andre Godin officer: CFO 440 DES CARMANTINES, LAVAL A8 H7X 0B6
Tommy Kenny officer: VP IP,Lgl Affairs - Subsidiary 88 CH. DES SAULES, ST-ADOLPHE D' HOWARD A8 J0T 2B0
Dana Matzen officer: VP Business+Corp. Development 4771 RUE SHERBROOKE O., WESTMOUNT A8 H3Z1G5
Ingrid Zerbe 10 percent owner, officer: Corporate Secretary 714 MAIN ROAD, HUDSON A8 J0P1H0
Rodolphe Obeid officer: Vice President, Operations 4779 RUE VILLERET, PIERREFOND A8 H9K1P6
Bernard Boudreau director 2 TURNMILL DR., HALIFAX A5 B3M4H2
John Edward Durham officer: Vice President Manufacturing 102 MAYFAIR, HUDSON A8 J0P1H0
Mark Nawacki director 118 ARLINGTON AVENUE, WESTMOUNT A8 H3Y2W4
Robert J. Bechard officer: VP Corporate Development 141 EASTON AVENUE, MONTREAL WEST A8 H4X 1L4

Intelgenx Technologies (Intelgenx Technologies) Headlines

From GuruFocus

IntelGenx and Arwan Enter into a Supply Agreement for RIZAPORT� in MENA Countries

By Stock market mentor Stock market mentor 01-23-2023

IntelGenx Reports First Quarter 2023 Financial Results

By sperokesalga sperokesalga 05-11-2023

IntelGenx Receives Fourth and Final Loan Tranche from atai

By Stock market mentor Stock market mentor 01-09-2023